Only inhibition of both IL-18 and IL-1β completely protects against mortality in a murine model of lethal endotoxemia [62], and combined blockade of IL-18 and IL-1β has been successfully implemented in a genetic form of MAS resulting from NLRC4 inflammasome hyperactivity [63]. Here, IL1B is linked to serum lipopolysaccharide activity.